CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.
Employees - 8,
CEO - Mr. Christopher B. Ehrlich M.B.A.,
Sector - Healthcare,
Country - US,
Market Cap - 5.09M
Altman ZScore(max is 10): -22.07, Piotroski Score(max is 10): 3, Working Capital: $-3688344, Total Assets: $6206929, Retained Earnings: $-70917853, EBIT: -11263536, Total Liabilities: $8101492, Revenue: $1162826
AryaFin Target Price - $0.03 - Current Price $0.91 - Analyst Target Price $11.00
| Ticker | CERO |
| Index | - |
| Curent Price | 0.91 |
| Change | -18.01% |
| Market Cap | 5.09M |
| Average Volume | 1.83M |
| Income | -8.30M |
| Sales | 0.00M |
| Book Value/Share | -1.56 |
| Cash/Share | 0.60 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | - |
| Moving Avg 20days | 23.40% |
| Moving Avg 50days | -18.23% |
| Moving Avg 200days | -89.34% |
| Shares Outstanding | 5.38M |
| Earnings Date | Feb 26 |
| Inst. Ownership | 4.80% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | - |
| Price/Book | - |
| Price/Cash | 1.53 |
| Price/FCF | - |
| Quick Ratio | 0.49 |
| Current Ratio | 0.49 |
| Debt/Equity | - |
| Return on Assets | -103.40% |
| Return on Equity | -4090.08% |
| Return on Investment | -8305.42% |
| Gross Margin | - |
| Ops Margin | - |
| Profit Margin | - |
| RSI | 50.71 |
| BETA(β) | 0.54 |
| From 52week Low | 70.49% |
| From 52week High | -99.47% |
| EPS | -38.99 |
| EPS next Year | -0.86 |
| EPS next Qtr | -5.96 |
| EPS this Year | 59.83% |
| EPS next 5 Year | 62.84% |
| EPS past 5 Year | - |
| Sales past 5 Year | 0.00% |
| EPS Y/Y | -234.31% |
| Sales Y/Y | - |
| EPS Q/Q | 106.14% |
| Sales Q/Q | - |
| Sales Surprise | - |
| EPS Surprise | - |
| ATR(14) | 0.16 |
| Perf Week | 47.50% |
| Perf Month | 7.65% |
| Perf Quarter | -63.30% |
| Perf Year | -99.33% |
| Perf YTD | -84.83% |
| Target Price | 11.00 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer